July 8, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) retained the title of the best-selling drug in Japan in June with 10.4 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm Encise. Chugai Pharmaceutical’s cancer...read more